Published in Mol Cancer Ther on October 01, 2010
Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer. J Exp Clin Cancer Res (2016) 1.41
The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicity. Sci Transl Med (2016) 1.40
Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol Cancer Ther (2010) 1.19
A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs. Proc Natl Acad Sci U S A (2014) 1.00
The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia. Clin Cancer Res (2013) 0.94
T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo. Cancer Med (2014) 0.90
Promising therapies in multiple myeloma. Blood (2015) 0.89
Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components. Toxins (Basel) (2011) 0.87
A molecular and structural mechanism for G protein-mediated microtubule destabilization. J Biol Chem (2010) 0.87
Identification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells. J Med Chem (2014) 0.85
Antibody-DM1 conjugates as cancer therapeutics. Cancer Lett (2011) 0.83
Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design. AAPS J (2016) 0.82
Ansamitocin P3 depolymerizes microtubules and induces apoptosis by binding to tubulin at the vinblastine site. PLoS One (2013) 0.81
Development and Validation of an Immuno-PET Tracer as a Companion Diagnostic Agent for Antibody-Drug Conjugate Therapy to Target the CA6 Epitope. Radiology (2015) 0.81
A novel MAPT mutation, G55R, in a frontotemporal dementia patient leads to altered Tau function. PLoS One (2013) 0.78
Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1). AAPS J (2016) 0.77
Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment. Am J Cancer Res (2016) 0.77
Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery. J Cancer Res Clin Oncol (2016) 0.76
Immunotherapeutic strategies to target prognostic and predictive markers of cancer. Biomark Med (2013) 0.76
Experimental approaches in the treatment of multiple myeloma. Ther Adv Hematol (2011) 0.76
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. Neoplasia (2016) 0.75
High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction. PLoS One (2015) 0.75
Noscapine recirculates enterohepatically and induces self-clearance. Eur J Pharm Sci (2015) 0.75
Modeling the effects of drug binding on the dynamic instability of microtubules. Phys Biol (2011) 0.75
Antibody-drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment. Interface Focus (2016) 0.75
Design, synthesis and biological evaluation of di-substituted noscapine analogs as potent and microtubule-targeted anticancer agents. Bioorg Med Chem Lett (2015) 0.75
Protein based therapeutic delivery agents: Contemporary developments and challenges. Biomaterials (2017) 0.75
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
Microtubules as a target for anticancer drugs. Nat Rev Cancer (2004) 13.93
Dynamic instability of individual microtubules analyzed by video light microscopy: rate constants and transition frequencies. J Cell Biol (1988) 9.32
A graphic method for the determination and presentation of binding parameters in a complex system. Anal Biochem (1967) 4.32
Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry (2010) 2.07
How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets (2007) 2.05
Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus. J Am Chem Soc (1972) 1.69
Recent developments in the maytansinoid antitumor agents. Chem Pharm Bull (Tokyo) (2004) 1.45
Antimitotic activity of the potent tumor inhibitor maytansine. Science (1975) 1.33
Structural insight into the inhibition of tubulin by vinca domain peptide ligands. EMBO Rep (2008) 1.32
Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res (2006) 1.30
Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem (2006) 1.29
Kinetic stabilization of microtubule dynamics at steady state in vitro by substoichiometric concentrations of tubulin-colchicine complex. Biochemistry (1995) 1.15
Interaction of vinblastine with steady-state microtubules in vitro. J Mol Biol (1982) 1.15
Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma. Mol Pharmacol (2006) 1.11
Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. J Pharmacol Exp Ther (2003) 1.07
Binding of vinblastine to stabilized microtubules. Mol Pharmacol (1989) 1.03
Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem (2010) 1.03
Differential effects of vinblastine on polymerization and dynamics at opposite microtubule ends. J Biol Chem (1996) 1.02
Preparation of microtubule protein and purified tubulin from bovine brain by cycles of assembly and disassembly and phosphocellulose chromatography. Methods Cell Biol (2010) 1.02
Maytansine binding to the vinblastine sites of tubulin. FEBS Lett (1977) 0.99
Effects of inhibitors of tubulin polymerization on GTP hydrolysis. J Biol Chem (1981) 0.97
Binding of maytansine to rat brain tubulin. Biochem Biophys Res Commun (1976) 0.94
Analysis of dynamic instability of steady-state microtubules in vitro by video-enhanced differential interference contrast microscopy with an appendix by Emin Oroudjev. Methods Cell Biol (2010) 0.90
Tubulin-colchicine complexes differentially poison opposite microtubule ends. Biochemistry (1984) 0.89
The maytansinoids. Isolation, structural elucidation, and chemical interrelation of novel ansa macrolides. J Org Chem (1977) 0.88
The neuroprotective peptide NAP does not directly affect polymerization or dynamics of reconstituted neural microtubules. J Alzheimers Dis (2010) 0.86
Effects of antimitotic agents on tubulin-nucleotide interactions. Pharmacol Ther (1991) 0.85
Effects of novel taxanes SB-T-1213 and IDN5109 on tubulin polymerization and mitosis. Chem Biol (2002) 0.84
Suppression of microtubule dynamics by binding of cemadotin to tubulin: possible mechanism for its antitumor action. Biochemistry (1998) 0.83
Binding of maytansinoids to tubulin. Biochem Pharmacol (1981) 0.82
Technology evaluation: cantuzumab mertansine, ImmunoGen. Curr Opin Mol Ther (2004) 0.81
A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res (2004) 0.81
Effects of Tau and MAP2 on the interaction of maytansine with tubulin: inhibitory effect of maytansine on vinblastine-induced aggregation of tubulin. Cancer Res (1985) 0.79
Different effects of tubulin ligands on the intrachain cross-linking of beta 1-tubulin. J Biol Chem (1984) 0.78
Microtubules as a target for anticancer drugs. Nat Rev Cancer (2004) 13.93
Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov (2010) 4.66
Building programmable jigsaw puzzles with RNA. Science (2004) 3.51
The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther (2005) 2.70
Molecular nanosprings in spider capture-silk threads. Nat Mater (2003) 2.23
Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry (2010) 2.07
Differential regulation of microtubule dynamics by three- and four-repeat tau: implications for the onset of neurodegenerative disease. Proc Natl Acad Sci U S A (2003) 2.06
Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther (2008) 1.78
Sacrificial bonds and hidden length: unraveling molecular mesostructures in tough materials. Biophys J (2005) 1.61
BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem (2005) 1.61
Inhibition of DNA decatenation, but not DNA damage, arrests cells at metaphase. Mol Cell (2004) 1.54
Long-term detrimental effect of bile duct injury on health-related quality of life. Arch Surg (2004) 1.49
Suppression of microtubule dynamic instability by the +TIP protein EB1 and its modulation by the CAP-Gly domain of p150glued. Biochemistry (2007) 1.48
Minor alteration of microtubule dynamics causes loss of tension across kinetochore pairs and activates the spindle checkpoint. J Biol Chem (2002) 1.44
Higher-order assembly of microtubules by counterions: from hexagonal bundles to living necklaces. Proc Natl Acad Sci U S A (2004) 1.39
Comparison of a new fibrin sealant with standard topical hemostatic agents. Arch Surg (2004) 1.39
Modulation of microtubule dynamics by tau in living cells: implications for development and neurodegeneration. Mol Biol Cell (2004) 1.34
Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res (2005) 1.34
Synchrotron X-ray diffraction study of microtubules buckling and bundling under osmotic stress: a probe of interprotofilament interactions. Phys Rev Lett (2004) 1.32
Myc stimulates B lymphocyte differentiation and amplifies calcium signaling. J Cell Biol (2007) 1.29
Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther (2009) 1.26
Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin. Mol Cancer Ther (2010) 1.23
Direct Costs of Acute Recurrent and Chronic Pancreatitis in Children in the INSPPIRE Registry. J Pediatr Gastroenterol Nutr (2016) 1.20
Inability of tau to properly regulate neuronal microtubule dynamics: a loss-of-function mechanism by which tau might mediate neuronal cell death. Biochim Biophys Acta (2005) 1.19
Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol Cancer Ther (2010) 1.19
Regulation of microtubule dynamic instability in vitro by differentially phosphorylated stathmin. J Biol Chem (2009) 1.18
Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology (2013) 1.18
Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest. Cancer Res (2003) 1.17
Three- and four-repeat tau regulate the dynamic instability of two distinct microtubule subpopulations in qualitatively different manners. Implications for neurodegeneration. J Biol Chem (2005) 1.17
Symptom management with massage and acupuncture in postoperative cancer patients: a randomized controlled trial. J Pain Symptom Manage (2007) 1.16
Suppression of centromere dynamics by Taxol in living osteosarcoma cells. Cancer Res (2003) 1.15
MCAK, a Kin I kinesin, increases the catastrophe frequency of steady-state HeLa cell microtubules in an ATP-dependent manner in vitro. FEBS Lett (2004) 1.15
Cationic liposome-microtubule complexes: pathways to the formation of two-state lipid-protein nanotubes with open or closed ends. Proc Natl Acad Sci U S A (2005) 1.14
Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells. Cancer Res (2004) 1.13
Origin of the long-range attraction between surfactant-coated surfaces. Proc Natl Acad Sci U S A (2005) 1.13
Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res (2010) 1.11
Kinetic suppression of microtubule dynamic instability by griseofulvin: implications for its possible use in the treatment of cancer. Proc Natl Acad Sci U S A (2005) 1.11
Dicoumarol: a unique microtubule stabilizing natural product that is synergistic with Taxol. Cancer Res (2003) 1.10
The crystal structure of polyhydroxybutyrate depolymerase from Penicillium funiculosum provides insights into the recognition and degradation of biopolyesters. J Mol Biol (2005) 1.08
Antimitotic antifungal compound benomyl inhibits brain microtubule polymerization and dynamics and cancer cell proliferation at mitosis, by binding to a novel site in tubulin. Biochemistry (2004) 1.08
FTDP-17 mutations compromise the ability of tau to regulate microtubule dynamics in cells. J Biol Chem (2006) 1.08
Atomic force microscopy imaging and pulling of nucleic acids. Curr Opin Struct Biol (2004) 1.06
Radial compression of microtubules and the mechanism of action of taxol and associated proteins. Biophys J (2005) 1.06
Model based dynamics analysis in live cell microtubule images. BMC Cell Biol (2007) 1.06
Determination of the size and chemical nature of the stabilizing "cap" at microtubule ends using modulators of polymerization dynamics. Biochemistry (2002) 1.04
Molecular aspects of boundary lubrication by human lubricin: effect of disulfide bonds and enzymatic digestion. Langmuir (2007) 1.03
Suppression of microtubule dynamic instability and turnover in MCF7 breast cancer cells by sulforaphane. Carcinogenesis (2008) 1.03
The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Mol Cancer Ther (2003) 1.03
2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules. Mol Cancer Ther (2006) 1.02
Preparation of microtubule protein and purified tubulin from bovine brain by cycles of assembly and disassembly and phosphocellulose chromatography. Methods Cell Biol (2010) 1.02
Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1'. J Med Chem (2003) 1.01
Antimitotic sulfonamides inhibit microtubule assembly dynamics and cancer cell proliferation. Biochemistry (2006) 1.01
Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem (2011) 1.01
World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany. MAbs (2011) 1.00
Stathmin strongly increases the minus end catastrophe frequency and induces rapid treadmilling of bovine brain microtubules at steady state in vitro. J Biol Chem (2005) 0.99
Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis. PLoS One (2013) 0.97
Determination of microtubule dynamic instability in living cells. Methods Cell Biol (2010) 0.94
Microtubule protofilament number is modulated in a stepwise fashion by the charge density of an enveloping layer. Biophys J (2006) 0.92
The role of halogen substitution in classical cannabinoids: a CB1 pharmacophore model. AAPS J (2004) 0.92
Stathmin family protein SCG10 differentially regulates the plus and minus end dynamics of microtubules at steady state in vitro: implications for its role in neurite outgrowth. Biochemistry (2007) 0.91
Artificial human telomeres from DNA nanocircle templates. Proc Natl Acad Sci U S A (2002) 0.91
Analysis of dynamic instability of steady-state microtubules in vitro by video-enhanced differential interference contrast microscopy with an appendix by Emin Oroudjev. Methods Cell Biol (2010) 0.90
Mechanism of action of the microtubule-targeted antimitotic depsipeptide tasidotin (formerly ILX651) and its major metabolite tasidotin C-carboxylate. Cancer Res (2007) 0.89
Ion specific effects in bundling and depolymerization of taxol-stabilized microtubules. Faraday Discuss (2013) 0.89
Intrinsically slow dynamic instability of HeLa cell microtubules in vitro. J Biol Chem (2002) 0.89
Synthesis and biological evaluation of 2-(3',4',5'-trimethoxybenzoyl)-3-amino 5-aryl thiophenes as a new class of tubulin inhibitors. J Med Chem (2006) 0.89
A molecular and structural mechanism for G protein-mediated microtubule destabilization. J Biol Chem (2010) 0.87
Treatment strategies for hepatocellular carcinoma in cirrhosis. J Gastrointest Surg (2003) 0.87
Second generation benzofuranone ring substituted noscapine analogs: synthesis and biological evaluation. Biochem Pharmacol (2011) 0.87
Hesperidin suppressed proliferations of both human breast cancer and androgen-dependent prostate cancer cells. Phytother Res (2010) 0.87
Economic and psychologic costs for maternal caregivers of gastrostomy-dependent children. J Pediatr (2004) 0.87
The neuroprotective peptide NAP does not directly affect polymerization or dynamics of reconstituted neural microtubules. J Alzheimers Dis (2010) 0.86
FTDP-17 mutations in Tau alter the regulation of microtubule dynamics: an "alternative core" model for normal and pathological Tau action. J Biol Chem (2008) 0.86
Caregiving time in sickle cell disease: psychological effects in maternal caregivers. Pediatr Blood Cancer (2007) 0.86
Effects of tetramethoxystilbene on hormone-resistant breast cancer cells: biological and biochemical mechanisms of action. Cancer Res (2007) 0.85
Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism. Bioconjug Chem (2011) 0.85